BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M. Simes, BioSante’s president & CEO will present a corporate update at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 11:00 am EDT.
Mr. Simes will provide an overview of BioSante, as well as an update on the LibiGel
(testosterone gel) Phase III clinical development program, and a review of published results using BioSante’s GVAX Cancer Immunotherapies in combination with ipilimumab (Ipi; Yervoy; BMS).
A live audio webcast of remarks by Mr. Simes may be accessed at
. The webcast will be archived for 90 days.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante´s products include LibiGel
(transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSante´s other products include a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc., and for which a New Drug Application (NDA) was approved by the FDA in February 2012, and the Pill-Plus™, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante´s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, is marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee. Additional information is available online at: